Catherine Geh

High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

Alex Pearson, Elizabeth Smyth, Irina S. Babina et al. · Cancer Discovery · 2016 · 276 citations · Full text

Medicine, Cancer Biology, Oncology +17

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Kate F. Byth, Andrew P. Thomas, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2009 · 122 citations

Medicine, Oncology, Pharmacology +17

Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B

Timo Vögtle, Sumana Sharma, Jun Mori et al. · eLife · 2019 · 64 citations · Full text

Life Sciences, Biochemistry, Cell Biology +17

A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.

Yung‐Jue Bang, Eric Van Cutsem, Wasat Mansoor et al. · Journal of Clinical Oncology · 2015 · 59 citations

Medicine, Oncology, Pharmacology +11

The cellular phenotype of AZ703, a novel selective imidazo[1,2-<i>a</i>]pyridine cyclin-dependent kinase inhibitor

Kate F. Byth, Catherine Geh, Cheryl Forder et al. · Molecular Cancer Therapeutics · 2006 · 48 citations · Full text

Medicine, Oncology, Pharmacology +15